TCGX Acquisition Corp.
corporate_fare Company Profile
TCGX Acquisition Corp. (NASDAQ:TCGX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 3 items for TCGX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-19, rated 9/10. Across its 3 most recent items scored 7 or higher, the top rating is 9/10, with 2 rated 8 or above. Recent SEC coverage for TCGX spans 8-K.
Recent high-impact activity:
- TCGX to Merge With TriGemX Bio in $160M-PIPE SPAC Deal at ~$599M Equity Value
- TCGX to Take Migraine Drug Developer TriGemX Public in $246M De-SPAC With $160M PIPE
- TCGX Acquisition Corp II Files for $100M IPO on Nasdaq
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 74,947 shares in TCGX as of the October 30, 2026 settlement, a 42.8% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 2.6% of TCGX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.